☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Tibsovo
Servier Reports the US FDA Acceptance of sNDA and Granted Priority Review of Tibsovo (ivosidenib) for R/R Myelodysplastic Syndrome...
August 16, 2023
Servier Presents Updated P-I Study Results of Tibsovo (ivosidenib) for IDH1-Mutated Relapsed/Refractory Myelodysplastic Syndromes...
June 12, 2023
Servier’s Tibsovo (ivosidenib) Receives EC’s Approval for IDH1-Mutated Acute Myeloid Leukemia and IDH1-Mutated Cholangiocarcinoma
May 11, 2023
Servier’s Tibsovo (ivosidenib) Receives the US FDA's Approval for the Treatment of IDH1-mutated Acute Myeloid Leukemia
May 26, 2022
Servier Publishes Results of Tibsovo (ivosidenib) in P-III (AGILE) Trial for IDH1-Mutated Acute Myeloid Leukemia in NEJM
April 21, 2022
Load more...
Back to Home